Skip to content

Resuscitation Quick Ribbon (First 2 Minutes)

High-Acuity
BiPAP Application:IPAP 10–12 cmH2O, EPAP 5 cmH2O immediately; offloads LV and drives fluid out of alveoli
High-Dose Nitroglycerin (SCAPE):SL 0.4–0.8 mg q2min OR IV infusion start 200–400 mcg/min (titrate down as SBP drops)
Loop Diuretic Timing:Hold Lasix in initial 15–30 min of SCAPE; give only after afterload is controlled
POCUS Lung Ultrasound:Bilateral multi-zone B-lines ('lung rockets') confirms cardiogenic pulmonary edema
Cardiogenic Shock First-Line:Norepinephrine 0.05–0.5 mcg/kg/min + Dobutamine 2.5–10 mcg/kg/min

Bottom-Line Clinical Pearl

Sympathetic Crashing Acute Pulmonary Edema (SCAPE) is a vascular crisis of extreme afterload mismatch, NOT fluid overload. Patients are drowning in their own sympathetic surge. Immediate management requires early BiPAP and aggressive high-dose intravenous Nitroglycerin (start infusion at 200–400 mcg/min or give 400–800 mcg SL / 2 mg IV boluses) to drop systemic vascular resistance rapidly. Loop diuretics play zero role in the first 15 minutes of SCAPE. In cardiogenic shock, Norepinephrine is the first-line vasopressor.

1. SCAPE: Pathophysiology of the Sympathetic Spiral

Sympathetic Crashing Acute Pulmonary Edema (SCAPE) is an extreme, life-threatening manifestation of acute decompensated heart failure that develops over minutes to hours. A sudden surge in catecholamines drives massive systemic vasoconstriction (skyrocketing afterload). The left ventricle cannot pump against this elevated systemic vascular resistance (SVR), causing left ventricular end-diastolic pressure to spike, transmitting backward into pulmonary capillaries and flooding alveoli. The resulting hypoxemia and air hunger trigger even greater sympathetic output, accelerating a lethal positive-feedback spiral.

ParameterGradual Decompensated Heart FailureSympathetic Crashing Acute Pulmonary Edema (SCAPE)
Time of OnsetDays to weeks (gradual weight gain, peripheral edema)Minutes to hours (sudden catastrophic distress)
Blood PressureNormal or mildly elevated (SBP 130–160 mmHg)EXTREMELY HYPERTENSIVE: SBP typically > 180–220 mmHg, DBP > 110 mmHg
Primary MechanismHypervolemia (true fluid overload, sodium/water retention)Extreme afterload mismatch / redistribution of blood from splanchnic circulation to lungs
Primary ResuscitationIntravenous Loop Diuretics (Furosemide 40–80 mg IV)AGGRESSIVE VASODILATION (High-dose Nitroglycerin) + BiPAP
Extremity ExamMarked peripheral lower extremity 3+ pitting edema, ascitesCool, pale, clammy extremities (intense peripheral vasoconstriction); minimal edema

2. Immediate Resuscitation: High-Dose Nitrates & BiPAP

The primary emergency goal in SCAPE is immediate reduction of systemic vascular resistance (afterload) to allow the left ventricle to eject blood forward, and positive airway pressure to recruit flooded alveoli:

InterventionStarting Dose & Administration ProtocolMechanisms & Physiological EffectTitration & Safety Targets
Non-Invasive Ventilation (BiPAP)IPAP 10–12 cmH2O, EPAP 5 cmH2O immediately; titrate IPAP up to 15–18 cmH2O as toleratedDrives fluid out of alveoli back into capillaries, reduces work of breathing, and decreases LV transmural wall stress and afterload.Avoid in vomiting, altered consciousness (GCS < 10), or facial trauma. Target SpO2 > 92%.
Sublingual Nitroglycerin (Bridge)0.4 mg to 0.8 mg sublingually every 2 minutes while establishing IV linesRapid mucosal absorption delivers high-dose veno- and arterio-dilation within 60–90 seconds.Continue until continuous IV nitroglycerin infusion is running.
IV Nitroglycerin Infusion (SCAPE Protocol)START AT 200–400 mcg/min (NOT 10–20 mcg/min!). Titrate down as blood pressure normalizesHigh doses (> 100–200 mcg/min) produce potent systemic ARTERIAL dilation, crashing SVR within minutes.Titrate down by 50–100 mcg/min every 5 minutes as SBP drops toward 140 mmHg. Discontinue if SBP < 100 mmHg.
Loop Diuretics (Furosemide / Bumetanide)Furosemide 40–80 mg IV (or 1–2x home oral dose)Venodilation initially, followed by delayed diuresis (onset 30–60 minutes).NEVER prioritize diuresis over nitrates in SCAPE. Give only AFTER afterload and distress are controlled.

3. Bedside Lung & Cardiac Ultrasound (POCUS)

Bedside point-of-care ultrasound (POCUS) differentiates acute heart failure from COPD/asthma in seconds, with sensitivity > 95% and specificity > 90% (far superior to chest radiography, which is delayed and normal in 15–20% of early pulmonary edema):

POCUS FindingSonographic LandmarkPathologic MechanismClinical Distinction
B-Lines ('Lung Rockets')Bilateral anterior and lateral chest zones (8-zone protocol)Hyperechoic, laser-like vertical artifacts originating from pleural line, extending to edge of screen without fading, moving with lung sliding.>= 3 B-lines per intercostal space in >= 2 bilateral zones confirms acute interstitial pulmonary edema (excludes pure COPD/asthma).
Plethoric IVCSubxiphoid longitudinal viewIVC diameter > 2.1 cm with < 50% inspiratory collapse.Reflects elevated central venous pressure and volume congestion.
Depressed LV Ejection FractionParasternal long and short axis viewsDecreased anterior mitral leaflet excursion (EPSS > 7 mm) and poor radial contraction.Identifies heart failure with reduced ejection fraction (HFrEF) vs preserved ejection fraction (HFpEF).

4. Cardiogenic Shock: Hemodynamics & Inotropes

When acute heart failure presents with severe hypotension (SBP < 90 mmHg, MAP < 65 mmHg, cardiac index < 2.2 L/min/m2) and end-organ hypoperfusion (cool clammy skin, oliguria, confusion, lactic acidosis), nitrates are contraindicated. The patient is in Cardiogenic Shock:

  • First-Line Vasopressor: Norepinephrine (0.05–0.5 mcg/kg/min). Multiple randomized trials (including the SOAP II trial) demonstrated that Norepinephrine is superior to Dopamine in cardiogenic shock, resulting in significantly fewer tachyarrhythmias and lower mortality.
  • Inotropic Support with Dobutamine: Once MAP is stabilized >= 65 mmHg with norepinephrine, add Dobutamine (2.5–20 mcg/kg/min). Dobutamine stimulates beta-1 adrenergic receptors to increase myocardial contractility and stroke volume.
  • Milrinone (Alternative Inodilator): Phosphodiesterase-3 inhibitor (0.25–0.75 mcg/kg/min). Increases contractility and causes pulmonary vasodilation without increasing myocardial oxygen consumption. Avoid in renal failure or severe hypotension.
  • Mechanical Circulatory Support: Consult interventional cardiology early for percutaneous ventricular assist device (Impella) or Intra-Aortic Balloon Pump (IABP) for refractory shock.
Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Acute Heart Failure, SCAPE & Cardiogenic Shock Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.